These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 29228637)

  • 1. Sorafenib improves lipiodol deposition in transarterial chemoembolization of Chinese patients with hepatocellular carcinoma: a long-term, retrospective study.
    Zheng L; Guo CY; Chen CS; Xiao JC; Hu HT; Cheng HT; Zong DW; Jiang L; Li HL
    Oncotarget; 2017 Nov; 8(57):97613-97622. PubMed ID: 29228637
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The safety and efficacy of transarterial chemoembolization combined with sorafenib and sorafenib mono-therapy in patients with BCLC stage B/C hepatocellular carcinoma.
    Wu FX; Chen J; Bai T; Zhu SL; Yang TB; Qi LN; Zou L; Li ZH; Ye JZ; Li LQ
    BMC Cancer; 2017 Sep; 17(1):645. PubMed ID: 28899349
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Nomogram Based on Preoperative Lipiodol Deposition after Sequential Retreatment with Transarterial Chemoembolization to Predict Prognoses for Intermediate-Stage Hepatocellular Carcinoma.
    Niu XK; He XF
    J Pers Med; 2022 Aug; 12(9):. PubMed ID: 36143160
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Transarterial chemoembolization plus lenvatinib versus transarterial chemoembolization plus sorafenib as first-line treatment for hepatocellular carcinoma with portal vein tumor thrombus: A prospective randomized study.
    Ding X; Sun W; Li W; Shen Y; Guo X; Teng Y; Liu X; Zheng L; Li W; Chen J
    Cancer; 2021 Oct; 127(20):3782-3793. PubMed ID: 34237154
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Survival outcomes of hepatic resection compared with transarterial chemoembolization or sorafenib for hepatocellular carcinoma with portal vein tumor thrombosis.
    Lee JM; Jang BK; Lee YJ; Choi WY; Choi SM; Chung WJ; Hwang JS; Kang KJ; Kim YH; Chauhan AK; Park SY; Tak WY; Kweon YO; Kim BS; Lee CH
    Clin Mol Hepatol; 2016 Mar; 22(1):160-7. PubMed ID: 27044767
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Microvascular Invasion as a Predictor of Response to Treatment with Sorafenib and Transarterial Chemoembolization for Recurrent Intermediate-Stage Hepatocellular Carcinoma.
    Peng Z; Chen S; Xiao H; Wang Y; Li J; Mei J; Chen Z; Zhou Q; Feng S; Chen M; Qian G; Peng S; Kuang M
    Radiology; 2019 Jul; 292(1):237-247. PubMed ID: 31135299
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tumor vascularity and lipiodol deposition as early radiological markers for predicting risk of disease progression in patients with unresectable hepatocellular carcinoma after transarterial chemoembolization.
    Chen CS; Li FK; Guo CY; Xiao JC; Hu HT; Cheng HT; Zheng L; Zong DW; Ma JL; Jiang L; Li HL
    Oncotarget; 2016 Feb; 7(6):7241-52. PubMed ID: 26769845
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of lipiodol infusion and drug-eluting beads transarterial chemoembolization of hepatocellular carcinoma in a real-life setting.
    Karalli A; Teiler J; Haji M; Seth E; Brismar TB; Wahlin S; Axelsson R; Stål P
    Scand J Gastroenterol; 2019 Jul; 54(7):905-912. PubMed ID: 31287338
    [No Abstract]   [Full Text] [Related]  

  • 9. Transarterial Chemoembolization (TACE) Combined with Sorafenib
    Ren B; Wang W; Shen J; Li W; Ni C; Zhu X
    J Cancer; 2019; 10(5):1189-1196. PubMed ID: 30854128
    [No Abstract]   [Full Text] [Related]  

  • 10. Sorafenib combined with transarterial chemoembolization versus transarterial chemoembolization alone for advanced-stage hepatocellular carcinoma: a propensity score matching study.
    Hu H; Duan Z; Long X; Hertzanu Y; Shi H; Liu S; Yang Z
    PLoS One; 2014; 9(5):e96620. PubMed ID: 24817002
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Transarterial Chemoembolization (TACE) Plus Sorafenib Compared to TACE Alone in Transplant Recipients with Hepatocellular Carcinoma: An Institution Experience.
    Abdelrahim M; Victor D; Esmail A; Kodali S; Graviss EA; Nguyen DT; Moore LW; Saharia A; McMillan R; Fong JN; Uosef A; Elshawwaf M; Heyne K; Ghobrial RM
    Cancers (Basel); 2022 Jan; 14(3):. PubMed ID: 35158918
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative effectiveness of traditional chemoembolization with or without sorafenib for hepatocellular carcinoma.
    Muhammad A; Dhamija M; Vidyarthi G; Amodeo D; Boyd W; Miladinovic B; Kumar A
    World J Hepatol; 2013 Jul; 5(7):364-71. PubMed ID: 23898369
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lipiodol deposition in portal vein tumour thrombus predicts treatment outcome in HCC patients after transarterial chemoembolisation.
    Yang Z; Zou R; Zheng Y; Qiu J; Shen J; Liao Y; Zhang Y; Wang C; Wang Y; Yuan Y; Li K; Zuo D; He W; Liu W; Li B; Yuan Y
    Eur Radiol; 2019 Nov; 29(11):5752-5762. PubMed ID: 30993438
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical impact and potential utility of non-enhanced computed tomography performed immediately after transarterial chemoembolization for hepatocellular carcinoma.
    Kim MY; Heo S; Choi S; Suh CH; Lee ES; Park HJ; Kim KW
    J Gastrointest Oncol; 2024 Jun; 15(3):1141-1152. PubMed ID: 38989419
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Transarterial chemoembolization (TACE) combined with apatinib versus TACE combined with sorafenib in advanced hepatocellular carcinoma patients: a multicenter retrospective study.
    Qiu Z; Shen L; Jiang Y; Qiu J; Xu Z; Shi M; Yu Z; Ma Y; He W; Zheng Y; Li B; Wang G; Yuan Y
    Ann Transl Med; 2021 Feb; 9(4):283. PubMed ID: 33708910
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Transarterial injection of (131)I-lipiodol, compared with chemoembolization, in the treatment of unresectable hepatocellular cancer.
    Marelli L; Shusang V; Buscombe JR; Cholongitas E; Stigliano R; Davies N; Tibballs J; Patch D; Meyer T; Burroughs AK
    J Nucl Med; 2009 Jun; 50(6):871-7. PubMed ID: 19443599
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Overall survival in response to sorafenib with transarterial chemoembolization for BCLC stage B hepatocellular carcinoma: propensity score analysis
.
    Huang Y; Chen B; Liu N; Li N; Dao H; Chen W; Yang J
    Int J Clin Pharmacol Ther; 2017 Jun; 55(6):498-508. PubMed ID: 28157070
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy of apatinib in patients with sorafenib-transarterial chemoembolization refractory hepatocellular carcinoma: a retrospective study.
    Cao Y; Ouyang T; Xiong F; Kan X; Chen L; Liang B; Zheng C
    Hepatol Int; 2021 Oct; 15(5):1268-1277. PubMed ID: 34415515
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Imaging biomarkers on Angio-CT for predicting the efficacy of transarterial chemoembolization in hepatocellular carcinoma.
    Wang H; Han Y; Chen G; Jin L
    Quant Imaging Med Surg; 2023 Jul; 13(7):4077-4088. PubMed ID: 37456312
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sorafenib in combination with transarterial chemoembolization improves the survival of patients with unresectable hepatocellular carcinoma: a propensity score matching study.
    Bai W; Wang YJ; Zhao Y; Qi XS; Yin ZX; He CY; Li RJ; Wu KC; Xia JL; Fan DM; Han GH
    J Dig Dis; 2013 Apr; 14(4):181-90. PubMed ID: 23324079
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.